A meta-analysis of tumor necrosis factor-α and FAS/FASL polymorphisms with risk of pre-eclampsia
暂无分享,去创建一个
W. Zhou | Lan Wang | Yuanyuan Yan | Zhen Chen | Yun Lin
[1] Yejun Wang,et al. Association of gene polymorphisms of FV, FII, MTHFR, SERPINE1, CTLA4, IL10, and TNFalpha with pre-eclampsia in Chinese women , 2016, Inflammation Research.
[2] A. Teixeira-Carvalho,et al. Severe preeclampsia: association of genes polymorphisms and maternal cytokines production in Brazilian population. , 2015, Cytokine.
[3] P. Žúbor,et al. TNF-α G308A Gene Polymorphism Has an Impact on Renal Function, Microvascular Permeability, Organ Involvement and Severity of Preeclampsia , 2014, Gynecologic and Obstetric Investigation.
[4] B. Nagy,et al. Genetic Aspects of Preeclampsia and the HELLP Syndrome , 2014, Journal of pregnancy.
[5] N. Al-Jameil,et al. A Brief Overview of Preeclampsia , 2013, Journal of clinical medicine research.
[6] C. Barrett,et al. Tumor Necrosis Factor‐Alpha, Interleukin‐6, and Interleukin‐10 Levels are Altered in Preeclampsia: A Systematic Review and Meta‐Analysis , 2013, American journal of reproductive immunology.
[7] R. Raghupathy. Cytokines as Key Players in the Pathophysiology of Preeclampsia , 2013, Medical Principles and Practice.
[8] B. Aggarwal,et al. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey. , 2012, Blood.
[9] Jiang-Bo Liu,et al. A meta-analysis of tumor necrosis factor-alpha, interleukin-6, and interleukin-10 in preeclampsia. , 2011, Cytokine.
[10] Weibo Liang,et al. RAD51 135G/C polymorphism and breast cancer risk: a meta-analysis from 21 studies , 2011, Breast Cancer Research and Treatment.
[11] A. Barakonyi,et al. Immunoactivation in preeclampsia: Vdelta2+ and regulatory T cells during the inflammatory stage of disease. , 2009, Journal of reproductive immunology.
[12] W. McGuire,et al. Tumour necrosis factor (‐308A) polymorphism in pre‐eclampsia: Meta‐analysis of 16 case–control studies , 2008, The Australian & New Zealand journal of obstetrics & gynaecology.
[13] A. Amirzargar,et al. Association of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in Iranian patients with pre-eclampsia. , 2008, American journal of reproductive immunology.
[14] R. Mattar,et al. Cytokine Genotyping in Preeclampsia , 2006, American journal of reproductive immunology.
[15] Louise Melvin. The relationship between condom use and herpes simplex virus acquisition , 2005, Journal of Family Planning and Reproductive Health Care.
[16] R. Ness,et al. Association between allelic variants in cytokine genes and preeclampsia. , 2005, American journal of obstetrics and gynecology.
[17] I. Sargent,et al. Latest Advances in Understanding Preeclampsia , 2005, Science.
[18] J. Kingdom,et al. Apoptosis in the Trophoblast—Role of Apoptosis in Placental Morphogenesis , 2004, The Journal of the Society for Gynecologic Investigation: JSGI.
[19] P. Husslein,et al. Tumor necrosis factor-alpha inhibits trophoblast migration through elevation of plasminogen activator inhibitor-1 in first-trimester villous explant cultures. , 2004, The Journal of clinical endocrinology and metabolism.
[20] S. Lévesque,et al. Implication of an AGT Haplotype in a Multigene Association Study With Pregnancy Hypertension , 2004, Hypertension.
[21] M. Sakai,et al. Th1/Th2 balance in preeclampsia. , 2003, Journal of reproductive immunology.
[22] G. Cooper,et al. A Novel Polymorphic CAAT/Enhancer-Binding Protein β Element in the FasL Gene Promoter Alters Fas Ligand Expression: A Candidate Background Gene in African American Systemic Lupus Erythematosus Patients1 , 2003, The Journal of Immunology.
[23] G. Mor,et al. Role of the Fas/Fas ligand system in female reproductive organs: survival and apoptosis. , 2002, Biochemical pharmacology.
[24] S. Thompson,et al. Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.
[25] G. Salvioli,et al. Genetic polymorphisms of Fas (CD95) and FasL (CD178) in human longevity: studies on centenarians , 2002, Cell Death and Differentiation.
[26] D. Sahota,et al. Increased placental apoptosis in pregnancies complicated by preeclampsia. , 2001, American journal of obstetrics and gynecology.
[27] M. McMahon,et al. Placental Apoptosis in Preeclampsia , 2000, Obstetrics and gynecology.
[28] J. Martin,et al. Expression of the placental cytokines tumor necrosis factor α, interleukin 1β, and interleukin 10 is increased in preeclampsia ☆ ☆☆ ★ , 1999 .
[29] Saito,et al. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia , 1999, Clinical and experimental immunology.
[30] S. Fisher,et al. Preeclampsia is associated with widespread apoptosis of placental cytotrophoblasts within the uterine wall. , 1999, The American journal of pathology.
[31] G. Mor,et al. Fas‐Fas Ligand System‐Induced Apoptosis in Human Placenta and Gestational Trophoblastic Disease , 1998, American journal of reproductive immunology.
[32] J. Roberts,et al. Endothelial Dysfunction in Preeclampsia , 1998, Seminars in reproductive endocrinology.
[33] G. Smith,et al. Bias in meta-analysis detected by a simple, graphical test , 1997, BMJ.
[34] S. Asa,et al. Expression of the apoptosis-inducing Fas ligand (FasL) in human first and third trimester placenta and choriocarcinoma cells. , 1997, The Journal of clinical endocrinology and metabolism.
[35] D. Green,et al. Unequal Death in T Helper Cell (Th)1 and Th2 Effectors: Th1, but not Th2, Effectors Undergo Rapid Fas/FasL-mediated Apoptosis , 1997, The Journal of experimental medicine.
[36] Marty W. Mayo,et al. TNF- and Cancer Therapy-Induced Apoptosis: Potentiation by Inhibition of NF-κB , 1996, Science.
[37] G. Chen,et al. Tumour necrosis factor‐alpha (TNF‐α) gene polymorphism and expression in pre‐eclampsia , 1996 .
[38] I. Behrmann,et al. Structure of the human APO‐1 gene , 1994, European journal of immunology.
[39] J. Inazawa,et al. Human Fas ligand: gene structure, chromosomal location and species specificity. , 1994, International immunology.
[40] A. Peaceman,et al. Tumor necrosis factor-alpha is elevated in plasma and amniotic fluid of patients with severe preeclampsia. , 1994, American journal of obstetrics and gynecology.
[41] T. Mosmann,et al. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? , 1993, Immunology today.
[42] N. Laird,et al. Meta-analysis in clinical trials. , 1986, Controlled clinical trials.
[43] W. Haenszel,et al. Statistical aspects of the analysis of data from retrospective studies of disease. , 1959, Journal of the National Cancer Institute.
[44] A. Štanclová,et al. Association of specific diplotypes defined by common rs1800682 and rare rs34995925 single nucleotide polymorphisms within the STAT1 transcription binding site of the FAS gene promoter with preeclampsia. , 2014, General physiology and biophysics.
[45] G. Mor,et al. The role of Fas mediated apoptosis in preeclampsia , 2005, Journal of perinatal medicine.
[46] J. N. Martin,et al. Expression of the placental cytokines tumor necrosis factor alpha, interleukin 1beta, and interleukin 10 is increased in preeclampsia. , 1999, American journal of obstetrics and gynecology.
[47] C. Y. Wang,et al. TNF- and cancer therapy-induced apoptosis: potentiation by inhibition of NF-kappaB. , 1996, Science.
[48] G. Chen,et al. Tumour necrosis factor-alpha (TNF-alpha) gene polymorphism and expression in pre-eclampsia. , 1996, Clinical and experimental immunology.